Cyclo Therapeutics Inc. Warrant (CYTHW)
$0.03
$0.00 (0.00%)As on 26-Mar-2025 09:30EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
10 Years Aggregate
CFO
$-73.26 Mln
EBITDA
$-80.04 Mln
Net Profit
$-81.70 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cyclo Therapeutics Inc. Warrant (CYTHW)
| -73.9 | -86.6 | -74.4 | -89.0 | -72.7 | -- | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Cyclo Therapeutics Inc. Warrant (CYTHW)
| -56.0 | -46.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 |
|
BSE Sensex
| 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Cyclo Therapeutics Inc. Warrant (CYTHW)
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta... cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc. Read more
-
CEO & Director
Mr. N. Scott Fine
-
CEO & Director
Mr. N. Scott Fine
-
Headquarters
Gainesville, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cyclo Therapeutics Inc. Warrant (CYTHW)
What is the current share price of Cyclo Therapeutics Inc Warrant (CYTHW) Today?
The share price of Cyclo Therapeutics Inc Warrant (CYTHW) is $0.03 (NASDAQ) as of 26-Mar-2025 09:30 EDT. Cyclo Therapeutics Inc Warrant (CYTHW) has given a return of -72.68% in the last 3 years.
What is the current PB & PE ratio of Cyclo Therapeutics Inc Warrant (CYTHW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-0.18 |
0.74 |
2023 |
-0.35 |
1.46 |
2022 |
-0.29 |
5.99 |
2021 |
-0.90 |
0.82 |
2020 |
-0.65 |
0.55 |
What is the 52 Week High and Low of Cyclo Therapeutics Inc Warrant (CYTHW)?
The 52-week high and low of Cyclo Therapeutics Inc Warrant (CYTHW) are Rs -- and Rs -- as of 05-Sep-2026.
What is the market cap of Cyclo Therapeutics Inc Warrant (CYTHW)?
Cyclo Therapeutics Inc Warrant (CYTHW) has a market capitalisation of $ 63 Mln as on 26-Mar-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Cyclo Therapeutics Inc Warrant (CYTHW)?
Before investing in Cyclo Therapeutics Inc Warrant (CYTHW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.